With the ClearSeq Cancer panels, Agilent also has available theNGS FFPE QC Kit for assessing the quality of genomic DNA priorto NGS target enrichment. Following sequencing, variants can beidentified in just a few minutes using Agilent SureCall software,which is available at no additional cost to Agilent customers. TheClearSeq Cancer solutions provide the confidence and answersneeded to drive clinical research decisions.
The ClearSeq Comprehensive Cancer panel, developed in collaborationwith researchers at the Washington University in St. Louis,targets 151 disease-associated genes implicated in a wide rangeof cancers (i.e., breast, lung, colorectal, AML). All coding exons,exon-intron boundaries and selected introns of these genes aretargeted (Table I). This panel is compatible with the SureSelectTarget Enrichment System.
貨號 | 產品 | 數量 | |
---|---|---|---|
5190-8011 | ClearSeq Comprehensive Cancer, XT | 16 rxns | |
5190-8012 | ClearSeq Comprehensive Cancer, XT | 96 rxns | |
5190-8013 | ClearSeq Comprehensive Cancer, XT | 96 rxns Auto | |
5190-8014 | ClearSeq Comprehensive Cancer Plus, XT | 16 rxns | |
5190-8015 | ClearSeq Comprehensive Cancer Plus, XT | 96 rxns | |
5190-8016 | ClearSeq Comprehensive Cancer Plus, XT | 96 rxns Auto | |
5190-8017 | ClearSeq Comprehensive Cancer, XT2 | 16 rxns | |
5190-8018 | ClearSeq Comprehensive Cancer, XT2 | 96 rxns | |
5190-8019 | ClearSeq Comprehensive Cancer, XT2 | 96 rxns Auto | |
5190-8020 | ClearSeq Comprehensive Cancer Plus, XT2 | 16 rxns | |
5190-8021 | ClearSeq Comprehensive Cancer Plus, XT2 | 96 rxns | |
5190-8022 | ClearSeq Comprehensive Cancer Plus, XT2 | 96 rxns Auto |